Treatment of Bleeding in Acquired von Willebrand Syndrome
For acute bleeding in acquired von Willebrand syndrome (AVWS), use desmopressin (DDAVP) 0.3 μg/kg IV as first-line therapy, followed by von Willebrand factor (VWF) concentrates (40 IU/kg) if bleeding persists or is unresponsive to DDAVP. 1, 2
Treatment Algorithm
Immediate Management of Active Bleeding
First-line: Desmopressin (DDAVP)
- Dose: 0.3 μg/kg IV (maximum 28 μg)
- Mechanism: Releases stored VWF from endothelial cells, increasing VWF levels 3-6 fold within 30-90 minutes 3
- Can repeat every 12-24 hours, but tachyphylaxis occurs after 3-5 doses due to endothelial VWF depletion 3
- Critical caveat: DDAVP may be ineffective in COVID-19 ARDS patients on ECMO due to depleted endothelial VWF stores 3
Second-line: VWF Concentrates (if DDAVP fails)
- Plasma-derived VWF concentrates (e.g., Humate P): 40 IU/kg IV once 3
- In adult ECMO patients with AVWS-related bleeding, this dose increased VWF:Ag from 263 to 394 IU/dL and VWF:RCo from 127 to 240 IU/dL within 2 hours 3
- Bleeding resolved within 24 hours in 40% and within 2-4 days in 60% of patients 3
- Thrombotic risk warning: 30% of treated ECMO patients developed thrombotic complications (LVAD thrombosis, DVT, ECMO circuit thrombosis) 3
Adjunctive Therapy
Prophylaxis Before Invasive Procedures
- VWF concentrates are preferred over DDAVP for procedural prophylaxis in AVWS 1, 4
- Use same dosing as for acute bleeding (40 IU/kg)
- DDAVP may be insufficient due to rapid VWF proteolysis by ADAMTS-13 in the high-shear environment 3
Refractory Bleeding (Third-line Options)
When bleeding persists despite DDAVP and VWF concentrates:
- Intravenous immunoglobulin (IVIG) - particularly effective when antibody-mediated clearance is suspected 2, 5
- Recombinant Factor VIIa - for patients unresponsive to standard therapy 6, 2
- Plasmapheresis - removes inhibitory antibodies in immune-mediated cases 6
Definitive Management: Treat the Underlying Condition
The most important long-term strategy is treating the underlying disease causing AVWS, which often results in complete remission of the bleeding disorder. 1, 4
Disease-Specific Considerations
- Lymphoproliferative disorders: Chemotherapy, immunosuppressants, or rituximab-based regimens achieve high response rates (18/22 cases) 7
- Waldenström macroglobulinemia: Use rituximab-based or bortezomib-based regimens (4/5 responses); avoid BTK inhibitors (zanubrutinib, ibrutinib) as they worsen bleeding through platelet inhibition (3/5 cases had bleeding worsening) 7
- Myeloproliferative neoplasms: Cytoreductive therapy reduces platelet-mediated VWF adsorption 8
- Cardiovascular disease (aortic stenosis, LVAD): Valve replacement or device optimization can rapidly resolve AVWS 9
- Autoimmune disorders: Immunosuppression targets antibody-mediated VWF clearance 8
Critical Diagnostic Considerations
Before treating, confirm AVWS diagnosis in patients with:
- New-onset bleeding with no personal/family bleeding history 1, 6
- Underlying lymphoproliferative, myeloproliferative, cardiovascular, or autoimmune disease 4
- Laboratory findings: Low VWF:RCo/VWF:Ag ratio (<0.7), loss of high-molecular-weight multimers 3, 8
In lymphoproliferative disorders, expect severe VWF functional defects with elevated VWFpp/VWF:Ag ratios (median 6.7), indicating accelerated clearance 8. In myeloproliferative neoplasms, expect mild multimer reduction with normal clearance (VWFpp/VWF:Ag ratio 1.0) and inverse correlation between platelet count and multimer loss 8.
Common Pitfalls
- Do not rely solely on DDAVP in patients with depleted endothelial stores (COVID-19, severe endothelial dysfunction) 3
- Monitor for thrombosis when using VWF concentrates, especially in ECMO patients or those with cardiovascular disease 3
- Avoid BTK inhibitors in Waldenström macroglobulinemia-associated AVWS due to platelet dysfunction 7
- Test for anti-VWF antibodies in lymphoproliferative or autoimmune cases (present in 30%), as this guides use of IVIG or plasmapheresis 8